

Current Report No 4/2023

Continuation of the review of strategic options - distribution of funds from the potential sale of technology

Management Board of Genomtec S.A. with its registered office in Wrocław (Issuer, Company) informs that in connection with the ongoing process of reviewing strategic options, today, i.e., March 21, 2023, it adopted a resolution on determining the method of distribution of funds from the potential sale of technology

According to the adopted resolution, the Issuer's Management Board will take all reasonable steps to ensure the Shareholders' participation in the benefits of the potential sale of the technology to the widest possible extent. This includes the call by the potential buyer for all of the Issuer's shares or allocating the entire profit obtained by the Company as a result of the potential sale of technology.

As at the date of publication of this report, the review of strategic options is in progress and no decisions have been made regarding the selection of a specific option to execute the strategy. The Issuer will inform about subsequent important stages of this process in the relevant reports.

